Cargando…

A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer

LESSONS LEARNED. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small cell lung cancer showed favorable efficacy. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small lung cancer showed tolerable toxicity. BACKGROUND. Although monotherapy w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Chihara, Yusuke, Date, Koji, Tamiya, Nobuyo, Takemura, Yoshizumi, Imabayashi, Tatsuya, Kaneko, Yoshiko, Yamada, Tadaaki, Ueda, Mikio, Arimoto, Taichiro, Uchino, Junji, Iwasaki, Yoshinobu, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459255/
https://www.ncbi.nlm.nih.gov/pubmed/30578309
http://dx.doi.org/10.1634/theoncologist.2018-0858
_version_ 1783410157285277696
author Yoshimura, Akihiro
Chihara, Yusuke
Date, Koji
Tamiya, Nobuyo
Takemura, Yoshizumi
Imabayashi, Tatsuya
Kaneko, Yoshiko
Yamada, Tadaaki
Ueda, Mikio
Arimoto, Taichiro
Uchino, Junji
Iwasaki, Yoshinobu
Takayama, Koichi
author_facet Yoshimura, Akihiro
Chihara, Yusuke
Date, Koji
Tamiya, Nobuyo
Takemura, Yoshizumi
Imabayashi, Tatsuya
Kaneko, Yoshiko
Yamada, Tadaaki
Ueda, Mikio
Arimoto, Taichiro
Uchino, Junji
Iwasaki, Yoshinobu
Takayama, Koichi
author_sort Yoshimura, Akihiro
collection PubMed
description LESSONS LEARNED. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small cell lung cancer showed favorable efficacy. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small lung cancer showed tolerable toxicity. BACKGROUND. Although monotherapy with cytotoxic agents including docetaxel or vinorelbine are recommended for elderly patients with advanced non‐small cell lung cancer (NSCLC), the outcome is not satisfactory. We evaluated the efficacy and safety of S‐1 and paclitaxel (PTX) as a first‐line cotreatment in elderly patients with advanced NSCLC. METHODS. Oral S‐1 was administered on days 1–14 every 3 weeks at 80, 100, and 120 mg per day for patients with body surface area < 1.25 m(2), 1.25–1.5 m(2), and > 1.5 m(2), respectively. PTX was administered at 80 mg/m(2) on days 1 and 8. The primary endpoint was response rate, and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. RESULTS. Seventeen patients were enrolled with response and disease control rates of 47.1% and 88.2%, respectively. Median PFS and OS were 5.6 and 35.0 months, respectively. Hematological grade 3 or 4 toxicities included leukopenia (55.8%), neutropenia (52.9%), febrile neutropenia (11.8%), and anemia (11.8%). Nonhematological grade 3 toxicities included stomatitis (23.5%), diarrhea (5.9%), and interstitial lung disease (5.9%), and grade 5 toxicities included interstitial lung disease (5.9%). CONCLUSION. This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.
format Online
Article
Text
id pubmed-6459255
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-64592552019-06-20 A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer Yoshimura, Akihiro Chihara, Yusuke Date, Koji Tamiya, Nobuyo Takemura, Yoshizumi Imabayashi, Tatsuya Kaneko, Yoshiko Yamada, Tadaaki Ueda, Mikio Arimoto, Taichiro Uchino, Junji Iwasaki, Yoshinobu Takayama, Koichi Oncologist Clinical Trial Results LESSONS LEARNED. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small cell lung cancer showed favorable efficacy. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small lung cancer showed tolerable toxicity. BACKGROUND. Although monotherapy with cytotoxic agents including docetaxel or vinorelbine are recommended for elderly patients with advanced non‐small cell lung cancer (NSCLC), the outcome is not satisfactory. We evaluated the efficacy and safety of S‐1 and paclitaxel (PTX) as a first‐line cotreatment in elderly patients with advanced NSCLC. METHODS. Oral S‐1 was administered on days 1–14 every 3 weeks at 80, 100, and 120 mg per day for patients with body surface area < 1.25 m(2), 1.25–1.5 m(2), and > 1.5 m(2), respectively. PTX was administered at 80 mg/m(2) on days 1 and 8. The primary endpoint was response rate, and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. RESULTS. Seventeen patients were enrolled with response and disease control rates of 47.1% and 88.2%, respectively. Median PFS and OS were 5.6 and 35.0 months, respectively. Hematological grade 3 or 4 toxicities included leukopenia (55.8%), neutropenia (52.9%), febrile neutropenia (11.8%), and anemia (11.8%). Nonhematological grade 3 toxicities included stomatitis (23.5%), diarrhea (5.9%), and interstitial lung disease (5.9%), and grade 5 toxicities included interstitial lung disease (5.9%). CONCLUSION. This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC. John Wiley & Sons, Inc. 2018-12-21 2019-04 /pmc/articles/PMC6459255/ /pubmed/30578309 http://dx.doi.org/10.1634/theoncologist.2018-0858 Text en © AlphaMed Press; the data published online to support this summary are the property of the authors
spellingShingle Clinical Trial Results
Yoshimura, Akihiro
Chihara, Yusuke
Date, Koji
Tamiya, Nobuyo
Takemura, Yoshizumi
Imabayashi, Tatsuya
Kaneko, Yoshiko
Yamada, Tadaaki
Ueda, Mikio
Arimoto, Taichiro
Uchino, Junji
Iwasaki, Yoshinobu
Takayama, Koichi
A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
title A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
title_full A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
title_fullStr A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
title_full_unstemmed A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
title_short A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
title_sort phase ii study of s‐1 and paclitaxel combination therapy as a first‐line treatment in elderly patients with advanced non‐small cell lung cancer
topic Clinical Trial Results
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459255/
https://www.ncbi.nlm.nih.gov/pubmed/30578309
http://dx.doi.org/10.1634/theoncologist.2018-0858
work_keys_str_mv AT yoshimuraakihiro aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT chiharayusuke aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT datekoji aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT tamiyanobuyo aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT takemurayoshizumi aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT imabayashitatsuya aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT kanekoyoshiko aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT yamadatadaaki aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT uedamikio aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT arimototaichiro aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT uchinojunji aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT iwasakiyoshinobu aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT takayamakoichi aphaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT yoshimuraakihiro phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT chiharayusuke phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT datekoji phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT tamiyanobuyo phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT takemurayoshizumi phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT imabayashitatsuya phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT kanekoyoshiko phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT yamadatadaaki phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT uedamikio phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT arimototaichiro phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT uchinojunji phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT iwasakiyoshinobu phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer
AT takayamakoichi phaseiistudyofs1andpaclitaxelcombinationtherapyasafirstlinetreatmentinelderlypatientswithadvancednonsmallcelllungcancer